Dabigatran Reversal Agent Effective in Clinical TestDabigatran Reversal Agent Effective in Clinical Test
The study included patients requiring urgent surgery, as well as those with life-threatening bleeding, but in all cases the dabigatran antidote effectively reversed the anticoagulant effect of the oral thrombin inhibitor. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 22, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Drug May Be Antidote to Bleeding Tied to Blood Thinner Pradaxa
Idarucizumab quickly reversed the effect in 100 percent of cases, study found
Source: HealthDay
Related MedlinePlus Pages: Blood Thinners, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 22, 2015 Category: Consumer Health News Source Type: news
Novel Agent Reverses the Anticoagulant Effects of Dabigatran — Completely and Quickly (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Idarucizumab, a monoclonal antibody fragment, completely and rapidly reverses the anticoagulant effects of dabigatran, according to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 22, 2015 Category: Primary Care Source Type: news
Perioperative Dabigatran Protocol Seems Safe, Doable, EffectivePerioperative Dabigatran Protocol Seems Safe, Doable, Effective
"Using a protocol similar to ours is probably more likely to keep the risk of bleeding and thromboembolic complications low compared with management according to physician preferences," say study authors. Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2015 Category: Consumer Health News Tags: Cardiology News Source Type: news
Pradaxa Lawsuit News: Settlements Disbursed, New Cases Filed
More than 3,000 claimants have already received settlement payments for Pradaxa lawsuits according to attorneys handling national Pradaxa claims alleging severe internal bleeding for the Onder Law...(PRWeb May 11, 2015)Read the full story at http://www.prweb.com/releases/pradaxa-lawsuit/bleeding-lawyer/prweb12712159.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 11, 2015 Category: Pharmaceuticals Source Type: news
Special MRI scan could identify stroke risk in people with atrial fibrillation
Atrial fibrillation is a heart rhythm disorder that affects millions of people. It can make you feel lousy. Even worse, it can cause potentially disabling or deadly strokes. A special MRI scan may — I stress the “may” — help identify people with atrial fibrillation who are at high risk of having a stroke. This could help many people with this condition to avoid taking warfarin or other clot-preventing medications for life.
A normal heartbeat starts in a cluster of cells called the pacemaker. It sits in the heart’s upper right chamber (the right atrium). These cells generate a pulse of electricity that...
Source: New Harvard Health Information - April 28, 2015 Category: Consumer Health News Authors: Howard LeWine, M.D. Tags: Heart Health atrial fibrillation MRI prevention special MRI scan Stroke Stroke Risk Source Type: news
Should NOACs Be Monitored Like Warfarin . . . by Pharmacists? Should NOACs Be Monitored Like Warfarin . . . by Pharmacists?
Dr John Mandrola describes the results of a trial studying adherence to dabigatran, which he calls "disruptive." theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2015 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
Pharmacists Key to Whether Patients Take Blood Thinners
In study, almost 30 percent of people with atrial fibrillation didn't use Pradaxa as instructed
Source: HealthDay
Related MedlinePlus Pages: Blood Thinners, Health Occupations (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 14, 2015 Category: Consumer Health News Source Type: news
Dabigatran adherence varies across VHA sites in US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2015 Category: Drugs & Pharmacology Source Type: news
An Aspirin a Day: Is the Benefit Worth the Risk?
Studies have shown that aspirin, the age old remedy for pain and fever, also thins the blood. Because of this property, it can also help to lower the chances of a heart attack or a stroke caused by a blood clot in the brain. And, although research has found that it only works in certain people (specifically, those with a history of heart attack or stroke) many Americans are inappropriately taking daily, low doses of aspirin as a preventative measure. In fact, researchers have found that about 12 percent of the of nearly 69,000 U.S. adults taking aspirin on a long-term basis should not have received the prescription in the ...
Source: Healthy Living - The Huffington Post - March 13, 2015 Category: Consumer Health News Source Type: news
FDA Approves Edoxaban for Stroke Prevention, DVT/PEFDA Approves Edoxaban for Stroke Prevention, DVT/PE
Edoxaban joins rivaroxaban, apixaban, and dabigatran as the fourth novel oral anticoagulant on the US market, but it does carry a boxed warning of limited efficacy in patients with creatinine clearances greater than 95 mL/min. FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 9, 2015 Category: Cardiology Tags: Cardiology News Alert Source Type: news
The New Health Care: The Drugs That Companies Promote to Doctors Are Rarely Breakthroughs
The money spent to influence doctors tends to be in the service of newer drugs that are “fairly redundant.” (Source: NYT Health)
Source: NYT Health - January 8, 2015 Category: Consumer Health News Authors: By CHARLES ORNSTEIN and RYANN GROCHOWSKI JONES ProPUBLICA Tags: Doctors Pfizer Inc PFE NYSE Drugs (Pharmaceuticals) Eliquis (Drug) Hospitals Bristol Myers Squibb Company BMY NYSE Novo Nordisk A/S NVO NYSE Pradaxa (Drug) Source Type: news
The New Health Care: The Drugs That Companies Promote to Doctors Are Rarely Breakthroughs
The money spent to influence doctors tends to be in the service of newer drugs that are “fairly redundant.” (Source: NYT)
Source: NYT - January 8, 2015 Category: American Health Authors: By CHARLES ORNSTEIN and RYANN GROCHOWSKI JONES ProPUBLICA Tags: Doctors Drugs (Pharmaceuticals) Eliquis (Drug) Hospitals Pradaxa (Drug) Source Type: news
NICE recommends Boehringer Ingelheim's Pradaxa to treat fatal blood clots in adults
The UK's National Institute for Health and Care Excellence (NICE) has recommended the anti-blood clotting drug dabigatran, Boehringer Ingelheim's Pradaxa, to treat fatal blood clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism) in… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - December 19, 2014 Category: Pharmaceuticals Source Type: news
NICE Gives 'Thumbs Up' to Dabigatran for VTENICE Gives 'Thumbs Up' to Dabigatran for VTE
The NICE decision is the final guidance issued and paves the way for reimbursement from the UK's National Health Service. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 18, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news
